SCHEMBL5957559

SCHEMBL5957559

O=S(=O)(c1ccc(Cl)cc1CCCl)c1ccc(Cl)cc1CCCl

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 1/20 0.40
CYP3A4 P08684 3/20 0.39
HIF1A Q16665 3/20 0.39
MEN1 O00255 2/20 0.39
HPGD P15428 2/20 0.39
ALOX15 P16050 2/20 0.39
KMT2A Q03164 2/20 0.39
HTT P42858 2/20 0.39
SLC22A1 O15245 1/20 0.39
USP2 O75604 1/20 0.39
LMNA P02545 1/20 0.39
HSP90AA1 P07900 1/20 0.39
MAPT P10636 1/20 0.39
HSPD1 P10809 1/20 0.39
HSPA5 P11021 1/20 0.39
IDO1 P14902 1/20 0.39
ALOX12 P18054 1/20 0.39
CASP1 P29466 1/20 0.39
BLM P54132 1/20 0.39
HSPE1 P61604 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2914223 0.84 TRPV4 (0.39) CNR2CYP3A4HIF1AMEN1HPGD
SCHEMBL11545414 0.80 DDR1 (0.44) CNR2CYP3A4HIF1AMEN1HPGD
SCHEMBL9820115 0.79 TAAR1 (0.36) HPGDKMT2AHTTMAPTALOX12
SCHEMBL5757189 0.79 PSEN1 (0.39) KMT2AUSP2SMN1; SMN2MAPK1AKR1B1
SCHEMBL11683029 0.78 MAPT (0.45) CNR2CYP3A4HIF1AMEN1HPGD
SCHEMBL9820025 0.77 MEN1 (0.57) CNR2CYP3A4HIF1AMEN1HPGD
SCHEMBL14395643 0.76 DDR1 (0.38) CNR2CYP3A4HIF1AMEN1HPGD
SCHEMBL10411133 0.75 ALDH1A1 (0.42) CYP3A4HIF1AMEN1ALOX15KMT2A
SCHEMBL10686098 0.75 ALDH1A1 (0.39) CYP3A4MEN1HPGDALOX15KMT2A
SCHEMBL11294816 0.74 HIF1A (0.41) CNR2CYP3A4HIF1AMEN1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118763273-A Sulfonyl deep eutectic polymer electrolyte and preparation and application thereof 青岛赛锂达储能产业技术研究院有限公司 2024-10-11 CN claimed
CN-118763273-A Sulfonyl deep eutectic polymer electrolyte and preparation and application thereof 青岛赛锂达储能产业技术研究院有限公司 2024-10-11 CN disclosed
US-20060040957-A1 BICYCLIC PYRIMIDINE MATRIX METALLOPROTEINASE INHIBITORS WARNER-LAMBERT COMPANY 2006-02-23 US disclosed
EP-1362054-A1 BICYCLIC PYRIMIDINE MATRIX METALLOPROTEINASE INHIBITORS Warner-Lambert Company LLC (US) 2003-11-19 EP disclosed
WO-2002064599-A1 BICYCLIC PYRIMIDINE MATRIX METALLOPROTEINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2002-08-22 WO disclosed
US-6200976-B1 FOR TREATING THROMBOSIS BOEHRINGER INGELHEIM PHARMA KG (DE) 2001-03-13 US disclosed
EP-0182299-B1 A CURABLE FLUOROELASTOMER COMPOSITION Asahi Kasei Kogyo Kabushiki Kaisha (JP) 1991-04-03 EP disclosed
US-4895840-A ANTIARRHYTHMIA AGENTS A. H. ROBINS COMPANY, INCORPORATED (US) 1990-01-23 US disclosed
EP-0295010-A1 Derivatives of alkylaminoalkyl ureas and cyanoguanidines A.H. ROBINS COMPANY, INCORPORATED (US) 1988-12-14 EP disclosed
US-4748208-A FLUOROPOLYMER, BIS/PHOSPHINE/IMINIUM HALIDE, POLYHYDROXY CURING AGENT ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) 1988-05-31 US disclosed
US-4724235-A N-(arylthioalkyl)-N'-(aminoalkyl)ureas useful in the treatment of arrhythmia A. H. ROBINS COMPANY, INCORPORATED (US) 1988-02-09 US disclosed
EP-0235463-A2 N-substituted-arylalkyl and arylalkylene piperidines as cardiovascular antihistaminic and antisecretory agents A.H. ROBINS COMPANY, INCORPORATED (a Delaware corporation) (US) 1987-09-09 EP disclosed
US-4597902-A TREATMENT OF CARDIAC ARRHYTHMIAS A. H. ROBINS COMPANY, INCORPORATED (US) 1986-07-01 US disclosed
EP-0182299-A2 A curable fluoroelastomer composition Asahi Kasei Kogyo Kabushiki Kaisha (JP) 1986-05-28 EP disclosed
EP-0066415-B1 N-(ARYLTHIOALKYL)-N'-(AMINOALKYL)UREAS A.H. ROBINS COMPANY, INCORPORATED (US) 1985-10-02 EP disclosed
EP-0066415-A2 N-(arylthioalkyl)-N'-(aminoalkyl)ureas A.H. ROBINS COMPANY, INCORPORATED (US) 1982-12-08 EP disclosed
US-4006118-A BROMINATED ALKOXYDIPHENYL SULFONE MARUBISHI YUKA KOGYO KABUSHIKI KAISHA (JA) 1977-02-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060040957-A1 BICYCLIC PYRIMIDINE MATRIX METALLOPROTEINASE INHIBITORS MMP13, MMP25, MMP15 CNR2 425/4885CYP3A4 1253/4885HIF1A 536/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.